Dr Reddy's API plant receives USFDA 483 with nine observations

By Dan Stanton

- Last updated on GMT

Inside a Dr Reddy's API facility
Inside a Dr Reddy's API facility

Related tags Dr reddy Food and drug administration

Dr Reddy’s says an API plant in India is unlikely to be subject to further regulatory enforcement after receiving a US FDA 483 with nine observations.

The Srikakulam facility in the Andhra Pradesh region of India was inspected by the US Food and Drug Administration (FDA) last week resulting in a Form 483 with nine observations, Shilpi Lathia – a company spokesperson – told in-Pharmatechnologist.com

“The observations were largely related to procedural and other compliances of the plant system,”​ she explained. As such “there is no implication on manufacturing and at this stage production continues as normal,”​ she added.

When asked what Dr Reddy’s Laboratories is doing to fix the issues, Lathia told us it is currently responding to the agency with its remediation plans and the firm is “confident it won’t lead to any further enforcement”​ such as a Warning Letter or import alert.

The plant manufactures bulk active pharmaceutical ingredients (APIs) - including bromfenacna, celecoxib, ibuprofen, ketorolac tromethamine, naproxen, naproxen sodium, glimepirid, linagliptin, liraglutide, and nateglinide - used in Dr Reddy’s finished formulated drugs for export to the US and EU.

This is not the first time Dr Reddy’s has fallen foul with the US. In August​ the US Government’s Consumer Product Safety Commission accused the firm of having violated childproof packaging rules, while an inspection of an API plant in Mexico in 2010​ was followed up with an FDA warning letter banning imports from the site.

Continued investment

Originally constructed in 2006 as part of a $100m investment​ in upping its network capacity, the site located in the Devunipalavalasa Special Economic Zone (SEZ) has been joined by a new oral solid dosage manufacturing facility last year.

According to Dr Reddy’s end of year report, the firm has “begun filing some of our new DMFs from this location and [it expects] to file some more during the year ending March 31, 2015.”

It continues: “To meet growing demand in regulated markets, we are in the process of obtaining approvals from the U.S. FDA for products to be manufactured from our recently commissioned oral solid dosage form facility.

“The new plant is intended for the manufacture of new molecules, and certain high volume products of ourGlobal Generics segment.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more